MEREO BIOPHARMA GROUP PLC's ticker is MREO and the CUSIP is 589492107. A total of 66 filers reported holding MEREO BIOPHARMA GROUP PLC in Q2 2022. The put-call ratio across all filers is 0.66 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $7,589 | -5.7% | 10,735 | 0.0% | 0.00% | – |
| Q4 2022 | $8,051 | -10.5% | 10,735 | 0.0% | 0.00% | – |
| Q3 2022 | $9,000 | -25.0% | 10,735 | 0.0% | 0.00% | – |
| Q2 2022 | $12,000 | 0.0% | 10,735 | 0.0% | 0.00% | – |
| Q1 2022 | $12,000 | -29.4% | 10,735 | 0.0% | 0.00% | -100.0% |
| Q4 2021 | $17,000 | -34.6% | 10,735 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $26,000 | -23.5% | 10,735 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $34,000 | -5.6% | 10,735 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $36,000 | -32.1% | 10,735 | -27.1% | 0.00% | -50.0% |
| Q4 2020 | $53,000 | -63.2% | 14,735 | -73.1% | 0.00% | -71.4% |
| Q3 2020 | $144,000 | -14.3% | 54,773 | 0.0% | 0.01% | -30.0% |
| Q2 2020 | $168,000 | +115.4% | 54,773 | -26.7% | 0.01% | +66.7% |
| Q1 2020 | $78,000 | -54.4% | 74,773 | +43.2% | 0.01% | -33.3% |
| Q4 2019 | $171,000 | -26.6% | 52,199 | -33.3% | 0.01% | -40.0% |
| Q3 2019 | $233,000 | +19.5% | 78,207 | +1.4% | 0.02% | +36.4% |
| Q2 2019 | $195,000 | – | 77,152 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 1,854,278 | $6,638,000 | 3.61% |
| Asymmetry Capital Management, L.P. | 739,812 | $2,649,000 | 1.21% |
| Affinity Asset Advisors, LLC | 625,000 | $2,238,000 | 1.19% |
| Tri Locum Partners LP | 728,710 | $2,609,000 | 0.95% |
| Boxer Capital, LLC | 6,226,673 | $22,291,000 | 0.72% |
| DAFNA Capital Management LLC | 668,148 | $2,392,000 | 0.71% |
| Vivo Capital, LLC | 4,220,938 | $15,111,000 | 0.67% |
| Delphi Management Partners VIII, L.L.C. | 256,734 | $919,000 | 0.60% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 280,000 | $1,002,000 | 0.58% |
| Rubric Capital Management LP | 1,853,417 | $6,635,000 | 0.49% |